FI
CRBP icon

Fosun International’s Corbus Pharmaceuticals CRBP Stock Holding History

Fosun International’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-23,336
Closed -$4.75M – 27
2016
Q3 		$4.75M Buy
+23,336
New +$2.9M 0.53% 21

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

Fosun International's CRBP Position: Q4 2016 in Review

Fosun International sold out of Corbus Pharmaceuticals (CRBP) in Q4 2016, closing a stake of 23,336 shares — an estimated $4.75M sold.

Fosun International first reported a position in CRBP in Q3 2016 and held it in 1 quarter. The position peaked at $4.75M in Q3 2016. 49 funds tracked by Wall St. Rank hold CRBP as of Q4 2016.

  • Fosun International reported no remaining Corbus Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Fosun International sold 23,336 Corbus Pharmaceuticals shares in Q4 2016, an estimated $4.75M.
  • Fosun International first reported a position in Corbus Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Fosun International's Corbus Pharmaceuticals position peaked at $4.75M in Q3 2016.
  • 49 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2016.

Based on Fosun International's 13F filing for Q4 2016, filed 13 Feb 2017.